BeOne Medicines (BEIGF) Short term Debt (2015 - 2026)

BeOne Medicines (BEIGF) has reported Short term Debt for 11 consecutive years, with $190.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Short term Debt fell 76.39% year-over-year to $190.9 million in Q2 2026; TTM through Jun 2026 was $190.9 million, a 76.39% decrease from a year earlier, with the FY2025 full-year figure at $57.3 million, down 93.27% from the prior year.
• Short term Debt was $190.9 million for Q2 2026 at BeOne Medicines, up from $116.1 million in the prior quarter.
• Over five years, Short term Debt peaked at $863.8 million in Q3 2024 and troughed at $57.3 million in Q4 2025.
• A 5-year average of $523.4 million and a median of $431.2 million in 2022 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt soared 193.45% in 2024 and slumped 93.27% in 2025, its largest moves.
• Over 5 years, Short term Debt stood at $329.0 million in 2022, then jumped by 109.25% to $688.4 million in 2023, then increased by 23.7% to $851.5 million in 2024, then tumbled by 93.27% to $57.3 million in 2025, then jumped by 233.19% to $190.9 million in 2026.
• The last three Short term Debt figures came in at $190.9 million (Q2 2026), $116.1 million (Q1 2026), and $57.3 million (Q4 2025), per Business Quant data.